Online citations, reference lists, and bibliographies.
← Back to Search

Nanoparticulate Devices For Brain Drug Delivery

C. Celia, D. Cosco, D. Paolino, M. Fresta
Published 2011 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The blood–brain barrier (BBB) limits the transport of therapeutic molecules from the blood compartment into the brain, thus greatly reducing the species of therapeutic compounds that can be efficiently accumulated in the central nervous system (CNS). Various strategies have been proposed for improving the delivery of drugs to this tissue, and numerous invasive and noninvasive methods have been proposed by different scientists in an attempt to circumvent the BBB and to increase the delivery of drug compounds into the brain. An interesting alternative, in the solution of this problem and also that of reaching a suitable target in the CNS, has recently been provided through the use of nanoparticulate colloidal devices as a noninvasive technique for brain drug delivery. These systems offer diverse advantages over invasive strategies, because (1) they are designed using biocompatible and biodegradable materials; (2) they avoid the disruption and/or modification of the BBB; and (3) they modulate the biopharmaceutical properties of the entrapped drugs. Moreover, the possibility of targeting specific brain tissue, thanks to ligands linked to the surface of the nanoparticulate colloidal devices, confers the necessary characteristics for the treatment of CNS pathologies to these drug carriers. The aim of this review is to focus on describing the main strategies in use for designing nanoparticulate colloidal devices for CNS delivery, their potentiality as noninvasive strategies in the delivery of drugs to the cerebral tissues, and their biological and clinical applications in cerebral drug delivery.  © 2010 Wiley Periodicals, Inc. Med Res Rev 31:716‐756, 2011
This paper references
10.1016/S0939-6411(02)00083-8
Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles.
J. X. Wang (2002)
Materials and biological aspects of synthetic polymers in controlled drug release systems: problems and challenges.
Bruck Sd (1988)
10.1016/S0169-409X(01)00105-3
Solid lipid nanoparticles: production, characterization and applications.
W. Mehnert (2001)
10.1016/J.IJPHARM.2005.03.031
Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain?
E. García-García (2005)
Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles
R. Alyautdin (1995)
10.1016/S0024-3205(97)00667-X
Survival rate improvement in a rat ischemia model by long circulating liposomes containing cytidine-5I-diphosphate choline.
M. Fresta (1997)
10.1023/A:1020159331420
Enzymatic Degradation of Dynasan 114 SLN – Effect of Surfactants and Particle Size
C. Olbrich (2002)
10.1016/S0169-409X(98)00088-X
The blood-brain barrier efflux transporters as a detoxifying system for the brain.
Terasaki (1999)
10.1007/s11095-008-9688-y
Development of a Smart Nano-vehicle to Target Cerebrovascular Amyloid Deposits and Brain Parenchymal Plaques Observed in Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Edward Agyare (2008)
10.1002/JPS.2600580916
Epoxy resin beads as a pharmaceutical dosage form. I. Method of preparation.
S. C. Khanna (1969)
10.1016/0006-8993(95)01375-X
Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections
U. Schroeder (1996)
10.1016/S0165-5728(99)00236-2
Antibody directed against mannan of the Mycobacterium tuberculosis cell envelope provokes blood–brain barrier breakdown
I. Namer (2000)
10.1016/S0169-409X(98)00087-8
Vector-mediated drug delivery to the brain.
Pardridge (1999)
10.1016/0378-5173(88)90037-3
Contact angles of surfactants with a potential to alter the body distribution of colloidal drug carriers on poly(methyl methacrylate) surfaces
S. Tröster (1988)
10.1083/JCB.138.4.877
A New Function for the LDL Receptor: Transcytosis of LDL across the Blood–Brain Barrier
B. Dehouck (1997)
10.1002/JPS.1122
Direct nose-brain transport of benzoylecgonine following intranasal administration in rats.
H. Chow (2001)
10.1016/S0169-409X(03)00041-3
Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications.
C. Vauthier (2003)
10.1006/PHRS.2000.0695
Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats.
A. Fundaró (2000)
Receptor-mediated endocytosis of transferrin at the blood-brain barrier.
R. Roberts (1993)
10.1007/s00262-006-0273-0
Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice
B. Gupta (2006)
10.1007/978-1-4615-0123-7_15
Blood-brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins.
W. Pardridge (2002)
Solid lipid nanoparticles (SLN): Phagocytic uptake, in vitro cytotoxicity and in vivo biodegradation
R H Mu¨ller (1999)
10.1016/J.BIOCEL.2004.10.004
Astrocytes: regulation of brain homeostasis via apolipoprotein E.
Jillian R. Gee (2005)
10.1074/jbc.274.11.7011
Receptor-mediated Transcytosis of Lactoferrin through the Blood-Brain Barrier*
C. Fillebeen (1999)
10.1016/J.SURNEU.2006.08.033
Nanotechnology approaches for drug and small molecule delivery across the blood brain barrier.
G. Silva (2007)
10.1101/GR.184901
The human ATP-binding cassette (ABC) transporter superfamily.
M. Dean (2001)
10.1002/JPS.2600590508
Bead polymerization technique for sustained-release dosage form.
S. C. Khanna (1970)
10.1023/A:1012043315093
Cytotoxicity of Solid Lipid Nanoparticles as a Function of the Lipid Matrix and the Surfactant
R. Mueller (2004)
10.1016/j.bmc.2007.12.051
Synthesis of chemically functionalized superparamagnetic nanoparticles as delivery vectors for chemotherapeutic drugs.
S. Hanessian (2008)
10.1016/0168-3659(94)90047-7
Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization
C. Schwarz (1994)
10.1586/14737175.8.1.75
Post-stroke depression
Jorge Moncayo Gaete (2008)
10.1046/j.1460-9568.2000.00078.x
Polysorbate‐80 coating enhances uptake of polybutylcyanoacrylate (PBCA)‐nanoparticles by human and bovine primary brain capillary endothelial cells
P. Ramge (2000)
Materials and biological aspects of synthetic polymers in controlled drug release systems: problems and challenges.
S. D. Bruck (1988)
10.1126/SCIENCE.285.5433.1466B
Introducing Proteins Into the Body's Cells
E. Strauss (1999)
10.1016/S0006-8993(00)02758-X
The 4F2hc/LAT1 complex transports l-DOPA across the blood–brain barrier
T. Kageyama (2000)
10.2165/00003495-199700544-00005
Polyethylene Glycol-Coated (Pegylated) Liposomal Doxorubicin
A. Gabizon (2012)
10.1016/S0378-5173(01)00660-3
Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages.
N. Schöler (2001)
10.1111/j.1471-4159.2005.03459.x
Tetanus toxin fragment C fusion facilitates protein delivery to CNS neurons from cerebrospinal fluid in mice
S. Benn (2005)
10.1016/J.JCONREL.2005.07.013
Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier.
L. Costantino (2005)
10.1016/J.JCONREL.2007.05.022
Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123.
G. Tosi (2007)
10.1016/j.brainres.2008.01.039
Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease
B. Wilson (2008)
10.1046/j.1471-4159.1998.71041761.x
Up‐Regulation of Blood‐Brain Barrier Short‐Form Leptin Receptor Gene Products in Rats Fed a High Fat Diet
R. Boado (1998)
10.1016/0142-9612(96)81411-6
Preparation and characterization of polyethyl-2-cyanoacrylate nanocapsules containing antiepileptic drugs.
M. Fresta (1996)
10.1016/J.EJPB.2006.10.019
Nanoparticles--an efficient carrier for drug delivery into the hair follicles.
J. Lademann (2007)
10.1186/1479-5876-6-80
Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells
H. Sarin (2008)
10.1073/PNAS.86.2.695
Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.
C. Cordon-Cardo (1989)
10.1016/S0169-409X(02)00118-7
Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations.
R. Mueller (2002)
10.1124/MOL.58.2.335
Oatp2 mediates bidirectional organic solute transport: a role for intracellular glutathione.
L. Li (2000)
10.1016/S0142-9612(03)00601-X
Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease.
C. Jollivet (2004)
10.1016/J.JCONREL.2006.10.015
Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants.
B. Petri (2007)
10.1016/S0939-6411(98)00074-5
Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase.
C. Freitas (1999)
10.1080/10611860600612953
Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles
V. Mishra (2006)
Blood–brain barrier produces significant efflux of L-aspartic acid but not D-aspartic acid: In vivo evidence using the brain efflux index method
K Hosoya (1999)
10.1007/PL00005725
Changes in the permeability of the blood-brain barrier following sodium dodecyl sulphate administration in the rat
A. Saija (1997)
10.1007/s11095-007-9514-y
Solid Lipid Nanoparticles as Delivery Systems for Bromocriptine
E. Esposito (2007)
10.1016/S0026-0495(98)90007-5
Human blood-brain barrier insulin-like growth factor receptor.
K. Duffy (1988)
On the interactions between pancreatic lipase and colipase and the substrate, and the importance of bile salts
Bengt Borgstriim (1975)
10.1016/S0169-409X(98)00090-8
Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems.
Bodor (1999)
10.1038/22124
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
D. Schenk (1999)
10.1016/0014-2999(72)90134-3
Ethanol enhancement of blood-brain barrier permeability to catecholamines in chicks.
J. Hanig (1972)
On the interactions between pancreatic lipase and colipase and the substrate, and the importance of bile salts.
B. Borgström (1975)
10.3109/10717549709051884
Adsorption of Brain Proteins on the Surface of Poly (D,L-lactide-co-glycolide) (PLGA) Microspheres
Preeti Saini (1997)
10.1016/j.ejpb.2008.04.018
Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: Formulation development and in vitro anticancer activity.
M. Pulkkinen (2008)
10.1016/j.jconrel.2008.10.016
Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations.
Kai-li Hu (2009)
10.1023/A:1007518525161
Functional Clarification of MCT1-Mediated Transport of Monocarboxylic Acids at the Blood-Brain Barrier Using In Vitro Cultured Cells and In Vivo BUI Studies
Y. Kido (2004)
10.1080/02652040600612439
Polymorphic behaviour of Compritol®888 ATO as bulk lipid and as SLN and NLC
E. Souto (2006)
10.1016/0169-409x(93)90048-9
Delivery of peptides and proteins through the blood-brain barrier.
U. Bickel (2001)
10.1016/j.jocn.2004.08.024
Drug-induced aseptic meningitis in suspected central nervous system infections
L. Kępa (2005)
10.1023/A:1018947208597
Indirect Evidence that Drug Brain Targeting Using Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles Is Related to Toxicity
J. Olivier (2004)
10.1016/J.IJPHARM.2006.06.012
Solid lipid nanoparticles incorporated in dextran hydrogels: a new drug delivery system for oral formulations.
M. A. Casadei (2006)
10.1002/JPS.20318
Nasal drug administration: potential for targeted central nervous system delivery.
Candace L. Graff (2005)
10.1208/aapsj060320
Particle size analysis: AAPS workshop report, cosponsored by the Food and Drug Administration and the United States Pharmacopeia
D. Burgess (2008)
10.2174/156720509787313961
Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.
A. Nordberg (2009)
10.1016/S0378-5173(00)00562-7
Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel.
A. Miglietta (2000)
10.1007/BF01191215
Scanning and transmission electron microscopic studies of microvascular pathology in the osmotically impaired blood-brain barrier
A. Lossinsky (1995)
10.1016/S0006-8993(99)01479-1
Peripheral injections of Freund's adjuvant in mice provoke leakage of serum proteins through the blood–brain barrier without inducing reactive gliosis
A. Rabchevsky (1999)
10.1016/J.BIOMATERIALS.2006.01.038
Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration.
X. Gao (2006)
10.1046/j.1365-2958.2000.02091.x
Analysis of mutants of tetanus toxin HC fragment: ganglioside binding, cell binding and retrograde axonal transport properties
K. Sinha (2000)
Long-circulating and target-specific nanoparticles: theory to practice.
S. Moghimi (2001)
10.1006/JMBI.1993.1321
Three-dimensional structure of the tetragonal crystal form of egg-white avidin in its functional complex with biotin at 2.7 A resolution.
L. Pugliese (1993)
Development and characterization of protein-loaded poly(lactideco-glycolide) nanospheres
Blanco (1997)
10.1016/S0939-6411(97)00056-8
Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres
M. D. Blanco (1997)
10.2174/157340707783220301
Innovative Drug Delivery Systems for the Administration of Natural Compounds
D. Paolino (2007)
10.1016/S0378-5173(98)00404-9
Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures.
C. Olbrich (1999)
10.1016/J.IJPHARM.2005.11.040
Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles.
K. Gao (2006)
10.1023/A:1022604120952
Direct Evidence That Polysorbate-80-Coated Poly(Butylcyanoacrylate) Nanoparticles Deliver Drugs to the CNS via Specific Mechanisms Requiring Prior Binding of Drug to the Nanoparticles
J. Kreuter (2004)
10.7326/0003-4819-105-1-82
Blood-brain barrier: interface between internal medicine and the brain.
W. Pardridge (1986)
Solid lipid nanoparticles (SLN): Phagocytic uptake, in vitro cytotoxicity and in vivo biodegradation, 2nd communication
RH Müller (1999)
10.1016/S0169-409X(02)00044-3
Nanoparticles in cancer therapy and diagnosis.
I. Brigger (2002)
10.1097/00019052-200012000-00004
Epidemiology of brain tumors.
F. Davis (2000)
10.1016/j.addr.2012.09.015
Nanoparticulate systems for brain delivery of drugs.
J. Kreuter (2001)
10.1016/J.IJPHARM.2005.10.010
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles.
Donald E. Owens (2006)
10.1023/A:1007045605751
The Choroid Plexuses and the Barriers Between the Blood and the Cerebrospinal Fluid
M. Segal (2004)
10.1111/j.1460-9568.2007.06018.x
Neuroprotective effects of novel phosphatidylglycerol‐based phospholipids in the 6‐hydroxydopamine model of Parkinson's disease
S. Crotty (2008)
10.1166/JNN.2006.441
The blood-brain barrier and brain drug delivery.
J. Koziara (2006)
10.1021/BM060711A
Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis.
H. R. Kim (2007)
10.1016/J.JCONREL.2005.02.005
Preformed microcapsules for loading and sustained release of ciprofloxacin hydrochloride.
Z. Mao (2005)
10.1126/SCIENCE.285.5433.1569
In vivo protein transduction: delivery of a biologically active protein into the mouse.
S. Schwarze (1999)
10.1097/WNR.0b013e32831c50df
Molecular basis of Parkinson's disease.
Y. Yang (2009)
10.1089/108729002761381320
Trafficking of intracerebroventricularly injected antisense oligonucleotides in the mouse brain.
N. Chauhan (2002)
10.1023/A:1011981927620
Combined Use of Carboxyl-Directed Protein Pegylation and Vector-Mediated Blood-Brain Barrier Drug Delivery System Optimizes Brain Uptake of Brain-Derived Neurotrophic Factor Following Intravenous Administration
W. Pardridge (2004)
10.1002/JPS.20357
Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration.
D. Das (2005)
10.3109/02652049809006836
Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study.
R. Alyautdin (1998)
10.1016/S0378-5173(00)00639-6
The role of plasma proteins in brain targeting: species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles.
A. Gessner (2001)
Drug delivery to the central nervous system: a review.
A. Misra (2003)
10.1016/J.IJPHARM.2006.02.045
Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals.
R. Mueller (2006)
10.1016/1357-4310(96)88720-X
Transporting therapeutics across the blood-brain barrier.
N. Abbott (1996)
10.1016/J.TUBE.2004.11.003
Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis.
R. Pandey (2005)
10.1016/J.ADDR.2007.04.011
Solid lipid nanoparticles for targeted brain drug delivery.
P. Blasi (2007)
10.1038/419863a
Breaking down the barriers
J. Emanuel (2002)
Glycopeptide analgesics. Drugs Future 2001;26:561–576
R Polt (2001)
10.1016/S0304-3940(01)01640-8
Uptake and efflux of the peptidic delta-opioid receptor agonist [D-penicillamine2,5]-enkephalin at the murine blood–brain barrier by in situ perfusion
C. Dagenais (2001)
10.1016/S0142-9612(00)00115-0
The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices.
R. Jain (2000)
10.1006/NBDI.1997.0134
Can Blood–Brain Barrier Play a Role in the Development of Cerebral Amyloidosis and Alzheimer's Disease Pathology
B. Zlokovic (1997)
10.1002/(SICI)1097-4547(19980915)53:6<637::AID-JNR1>3.0.CO;2-6
Role of the CNS microvascular pericyte in the blood‐brain barrier
R. Balabanov (1998)
10.1080/03639040600640006
The Metabolism of Fatty Alcohols in Lipid Nanoparticles by Alcohol Dehydrogenase
X. Dong (2006)
10.1172/JCI2029
Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer.
J. Mackic (1998)
10.1016/J.JCONREL.2006.12.012
Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain.
J. Kreuter (2007)
The manufacturing techniques of various drug loaded biodegradable poly(lactideco-glycolide) (PLGA) devices. Biomaterials 2000;21:2475–2490
RA Jain (2000)
10.2147/IJN.S596
Drug delivery and nanoparticles: Applications and hazards
W. D. de Jong (2008)
10.1038/onc.2008.344
Tight junction-based epithelial microenvironment and cell proliferation
S. Tsukita (2008)
10.1016/j.drudis.2008.09.005
The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?
L. Juillerat-Jeanneret (2008)
10.1016/S0378-5173(01)00882-1
Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages.
N. Schöler (2002)
10.1016/S0168-3659(99)00007-3
Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain.
S. Yang (1999)
10.1007/s11095-007-9379-0
Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation
A. R. Jones (2007)
10.1002/JPS.10556
Surface modification of poly(glycolic acid) (PGA) for biomedical applications.
Kyung-Bok Lee (2003)
Glycopeptide analgesics
R Polt (2001)
10.1016/S0168-3659(99)00063-2
Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting.
M. Peracchia (1999)
10.1016/S0168-3659(99)00250-3
Development of microspheres for neurological disorders: from basics to clinical applications.
J. Benoit (2000)
10.2217/17435889.2.6.789
Characterization of nanoparticles for therapeutics.
J. B. Hall (2007)
10.1016/s1359-6446(00)01632-9
Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1).
H. Kusuhara (2001)
10.1016/j.jconrel.2005.09.053
Barriers to carrier mediated drug and gene delivery to brain tumors.
Grace H Huynh (2006)
10.1046/j.1471-4159.1994.62031089.x
Localization of Drug‐Metabolizing Enzyme Activities to Blood‐Brain Interfaces and Circumventricular Organs
J. Ghersi-Egea (1994)
10.1021/JS980084Y
Nanoparticle technology for delivery of drugs across the blood-brain barrier.
U. Schroeder (1998)
Opioid Analgesics: Chemistry and Receptors
A. F. Casy (1986)
10.1517/17425247.5.6.629
Biodegradable polymeric nanocarriers for pulmonary drug delivery.
E. Rytting (2008)
10.1046/j.1471-4159.2002.00840.x
Expression of the neonatal Fc receptor (FcRn) at the blood–brain barrier
F. Schlachetzki (2002)
10.1023/A:1016234226404
Enhanced Therapeutic Effect of Cytidine-5′ -Diphosphate Choline when Associated with GM1 Containing Small Liposomes as Demonstrated in a Rat Ischemia Model
M. Fresta (2004)
10.1016/j.biomaterials.2008.07.008
The role of daidzein-loaded sterically stabilized solid lipid nanoparticles in therapy for cardio-cerebrovascular diseases.
Y. Gao (2008)
10.1016/J.IJPHARM.2006.10.021
Nanoparticles--a historical perspective.
J. Kreuter (2007)
10.3171/JNS.1997.87.5.0694
Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases.
M. Chamberlain (1997)
10.1172/JCI109509
Osmotic blood-brain barrier disruption. Computerized tomographic monitoring of chemotherapeutic agent delivery.
E. Neuwelt (1979)
10.3109/10717549709052017
Carboplatin-Loaded PLGA Microspheres for Intracerebral Implantation: In Vivo Characterization.
W. Chen (1997)
10.1517/17425247.5.4.371
Advances in PEGylation of important biotech molecules: delivery aspects.
S. Ryan (2008)
Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery
E. B. Soutoa (2004)
10.1016/S0168-3659(97)00046-1
Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential
K. Westesen (1997)
10.1093/JAC/DKL128
Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model.
R. Pandey (2006)
10.1016/J.BIOMATERIALS.2007.08.011
Tetanus toxin C fragment-conjugated nanoparticles for targeted drug delivery to neurons.
Seth A. Townsend (2007)
10.1089/DNA.1991.10.399
Molecular and cellular mechanisms of receptor-mediated endocytosis.
V. Brown (1991)
10.1016/J.ADDR.2003.12.002
Solid lipid nanoparticles for parenteral drug delivery.
S. Wissing (2004)
10.1023/A:1018888927852
Body Distribution of Camptothecin Solid Lipid Nanoparticles After Oral Administration
Shicheng Yang (2004)
10.1208/aapsj060323
Etoposide-incorporated tripalmitin nanoparticles with different surface charge: Formulation, characterization, radiolabeling, and biodistribution studies
L. H. Reddy (2008)
10.5414/CPP38069
P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs.
M. Fromm (2000)
10.1016/J.EJPB.2005.03.006
Characterisation of surface-modified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier.
M. Schubert (2005)
10.1016/J.EJPS.2005.10.004
Structural investigations on lipid nanoparticles containing high amounts of lecithin.
M. Schubert (2006)
The human brain: An introduction to its functional anatomy
J. Nolte (2002)
10.1016/S0168-3659(97)00061-8
Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood–brain barrier using surfactant-coated nanoparticles
J. Kreuter (1997)
10.1016/S0168-3659(01)00486-2
Design of biodegradable particles for protein delivery.
A. Vila (2002)
10.1016/J.DRUDIS.2006.10.013
Blood-brain barrier delivery.
W. Pardridge (2007)
10.1007/BF00258124
The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80
M. N. Azmin (2004)
10.2174/156720106776359230
A review of nanocarrier-based CNS delivery systems.
S. Tiwari (2006)
[Toxicity of drugs on nasal mucocilia and the method of its evaluation].
X. Jiang (1995)
10.1016/S0169-409X(02)00172-2
Drug efflux transporters in the CNS.
Haiying Sun (2003)
10.1016/J.JCONREL.2005.06.006
Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration.
K. Manjunath (2005)
10.1016/J.BIOMATERIALS.2007.11.014
Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier.
L. Liu (2008)
Human blood–brain barrier receptors for Alzheimer’s amyloid-b 1–40
J Mackinc (1998)
Enzymatic degradation of Dynasan 114 solid lipid nanoparticles (SLN)—Effect of surfactants and particle size
C Olbrich (2002)
10.1002/JPS.2600651217
Polymerized micelles and their use as adjuvants in immunology.
G. Birrenbach (1976)
10.1023/A:1018983904537
Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles
A. Gulyaev (2004)
10.1016/J.BIOMATERIALS.2006.04.026
Nanoparticulate drug carriers based on hybrid poly(D,L-lactide-co-glycolide)-dendron structures.
L. Costantino (2006)
10.1016/J.JCONREL.2005.07.024
Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease.
Celeste A. Roney (2005)
10.1016/J.BIOMATERIALS.2003.09.087
Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain.
Wangqiang Sun (2004)
10.1074/JBC.M104833200
Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine.
Z. Chen (2001)
10.1016/S0167-7799(97)01036-6
Biomedical applications of nanotechnology--implications for drug targeting and gene therapy.
S. Davis (1997)
10.1016/S1734-1140(12)70901-5
Nanoparticles as drug delivery systems.
A. Z. Wilczewska (2012)
Drug delivery systems. In: Webster JG, editor. Encyclopedia of medical devices and instrumentation. 2nd edition
D Paolino (2006)
10.1016/j.nbd.2003.12.016
The blood–brain barrier: an overview: Structure, regulation, and clinical implications
P. Ballabh (2004)
10.1023/A:1012098005098
Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles
R. Alyautdin (2004)
10.1172/JCI119832
Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters.
D. B. Agus (1997)
10.1007/s11095-007-9374-5
Contribution of Carrier-Mediated Transport Systems to the Blood–Brain Barrier as a Supporting and Protecting Interface for the Brain; Importance for CNS Drug Discovery and Development
S. Ohtsuki (2007)
Physiology and pharmacological role of the blood-brain barrier.
J. Bernacki (2008)
10.1016/S0939-6411(00)00087-4
Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art.
R. Mueller (2000)
10.1016/S0168-3659(99)00060-7
Future challenges for drug delivery.
D. Breimer (1999)
10.1006/PHRS.1999.0509
Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN).
G. Zara (1999)
10.1016/J.IJPHARM.2004.02.032
Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery.
E. Souto (2004)
10.1186/1743-8977-3-11
The potential risks of nanomaterials: a review carried out for ECETOC
P. Borm (2006)
10.1080/1061186031000086108
In Vitro and In Vivo Study of Solid Lipid Nanoparticles Loaded with Superparamagnetic Iron Oxide
E. Peira (2003)
10.1016/j.jconrel.2007.12.018
Potential of solid lipid nanoparticles in brain targeting.
I. P. Kaur (2008)
10.1046/j.1471-4159.2003.02063.x
The l‐isomer‐selective transport of aspartic acid is mediated by ASCT2 at the blood–brain barrier
K. Tetsuka (2003)
Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.
A. Gabizon (1997)
Drug delivery systems.
H. P. Noteborn (1989)
The Monro-Kellie hypothesis: Applications in CSF volume depletion
B. Mokri (2001)



This paper is referenced by
10.1517/17460441.2012.677025
Designing prodrugs for the treatment of Parkinson's disease
P. Sozio (2012)
10.1080/03639045.2017.1391835
Development and characterization of cationic solid lipid nanoparticles for co-delivery of pemetrexed and miR-21 antisense oligonucleotide to glioblastoma cells
Berrin Küçüktürkmen (2018)
Polycyclic compounds as carriers for neuroactive non- steroidal anti-inflammatory drugs
Modupe K. Abaniwonda (2017)
10.1016/j.jconrel.2014.03.006
The role of glucose transporters in the distribution of p-aminophenyl-α-d-mannopyranoside modified liposomes within mice brain.
Dan Du (2014)
10.1016/j.biomaterials.2014.04.088
Targeting the thyroid gland with thyroid-stimulating hormone (TSH)-nanoliposomes.
D. Paolino (2014)
10.1016/j.ejps.2015.06.024
Synthesis and characterization of a PAMAM dendrimer nanocarrier functionalized by SRL peptide for targeted gene delivery to the brain.
A. Zarebkohan (2015)
10.3109/1061186X.2013.824457
CNS drug targeting: have we travelled in right path?
A. Punitha (2013)
Ligand-mediated transport of drug delivery devices across the blood-brain barrier
Julia V. Georgieva (2012)
10.2174/1573413711666150706183157
Stimuli-Responsive Nanocarriers for Drug Delivery to the Central Nervous System
F. Liu (2015)
10.1016/j.jconrel.2020.02.020
Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting.
Mukta Agrawal (2020)
10.1007/s12247-018-9365-6
Central Composite Design for Optimization of Zoledronic Acid Loaded PLGA Nanoparticles
O. M. Saka (2018)
10.4274/tjps.84803
In Situ Hydrogel Formulation for Intra-Articular Application of Diclofenac Sodium-Loaded Polymeric Nanoparticles
Berrin Küçüktürkmen (2017)
10.1007/978-1-4614-9105-7_13
Pharmacoeconomic Considerations in CNS Drug Development
D. L. Gray (2014)
10.2217/nnm.10.107
Properties, engineering and applications of lipid-based nanoparticle drug-delivery systems: current research and advances.
Joshua Buse (2010)
10.1016/j.biomaterials.2016.04.021
Pluronic P85-coated poly(butylcyanoacrylate) nanoparticles overcome phenytoin resistance in P-glycoprotein overexpressing rats with lithium-pilocarpine-induced chronic temporal lobe epilepsy.
Ziyan Fang (2016)
10.2174/1389450111314090013
Differential scanning calorimetry as a tool to investigate the transfer of anticancer drugs to biomembrane model.
M. G. Sarpietro (2013)
10.2147/IJN.S58362
Physicochemical features and transfection properties of chitosan/poloxamer 188/poly(D,L-lactide-co-glycolide) nanoplexes
D. Cosco (2014)
10.1039/C5RA12588J
Thyroid-stimulating hormone (TSH)-armed polymer–lipid nanoparticles for the targeted delivery of cisplatin in thyroid cancers: therapeutic efficacy evaluation
Xue-Jun Gao (2015)
10.1016/j.ijpharm.2016.07.066
Angiopep2-functionalized polymersomes for targeted doxorubicin delivery to glioblastoma cells.
P. Figueiredo (2016)
10.2217/nnm.15.29
PEG-g-chitosan nanoparticles functionalized with the monoclonal antibody OX26 for brain drug targeting.
Yuliana Monsalve (2015)
10.1016/j.ejps.2020.105561
Guided bone regeneration by the development of alendronate sodium loaded in-situ gel and membrane formulations.
Umut Can Öz (2020)
10.1002/med.21252
Medicinal Chemistry Based Approaches and Nanotechnology‐Based Systems to Improve CNS Drug Targeting and Delivery
P. Vlieghe (2013)
10.2147/DDDT.S100075
Drug delivery in overcoming the blood–brain barrier: role of nasal mucosal grafting
C. Marianecci (2017)
10.2147/IJN.S258311
PEG-Ceramide Nanomicelles Induce Autophagy and Degrade Tau Proteins in N2a Cells
Jie Gao (2020)
10.1016/j.ijpharm.2011.07.035
Lipid nanoparticles for brain targeting I. Formulation optimization.
P. Blasi (2011)
10.22037/IJPR.2016.1920
SRL-Coated PAMAM Dendrimer Nano-Carrier for Targeted Gene Delivery to the Glioma Cells and Competitive Inhibition by Lactoferrin
A. Zarebkohan (2016)
10.1016/j.ijpharm.2017.08.073
Peptide modified mesenchymal stem cells as targeting delivery system transfected with miR-133b for the treatment of cerebral ischemia.
B. Huang (2017)
10.1002/mabi.201500388
Amphiphilic Copolymers Shuttle Drugs Across the Blood-Brain Barrier.
Mirjam Clemens-Hemmelmann (2016)
10.1016/j.drudis.2011.02.006
Supramolecular devices to improve the treatment of brain diseases.
D. Paolino (2011)
Stabilisation of Tyrosine Hydroxylase in Nanoparticles for Enzyme Replacement Therapy
Maria Teresa Bezem (2012)
10.3390/nano6050092
PDE5 Inhibitors-Loaded Nanovesicles: Physico-Chemical Properties and In Vitro Antiproliferative Activity
R. F. De Rose (2016)
10.1016/j.jconrel.2010.11.033
Neurotherapeutic applications of nanoparticles in Alzheimer's disease.
J. Sahni (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar